This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alazzouzi, H. Articles by Arango, D. Search for Related Content PubMed PubMed Citation Articles by Alazzouzi, H. Articles by Arango, D.

SMAD4 as a Prognostic Marker in Colorectal Cancer

Authors' Affiliations: ¹ Centre d'Investigacions en Bioquimica i Biologia Molecular, Hospital Universitari Vall d'Hebron, Barcelona, Spain; ² Department of Medical Genetics, Biomedicum Helsinki, Helsinki, Finland; and ³ Department of Pathology, Haartman Institute, University of Helsinki; ⁴ Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland; ⁵ Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland; and ⁶ Gene Cancer Therapy Group, Rational Drug Design Program, University of Helsinki and Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland

Requests for reprints: Diego Arango, Department of Medical Genetics, Biomedicum Helsinki University of Helsinki, Room B520a, P.O. Box 63 (Haartmaninkatu 8), FIN-00014 Helsinki, Finland. Phone: 358-9-19125600; Fax: 358-9-19125105; E-mail: diego.arango{at}helsinki.fi.

More than 50% of patients with Dukes C colorectal cancer have disease recurrence and die within 5 years after surgical removal of their primary tumor. It is currently not possible to distinguish patients with good and bad prognosis. SMAD4 is an important tumor suppressor gene that mediates transforming growth factor-ß superfamily signaling and is located in chromosome 18q21, a region with frequent genetic losses in these tumors. Allelic imbalance in 18q has been linked to poor prognosis in a subset of colorectal cancer patients. Therefore, we generated a tissue microarray containing triplicate tumor samples from 86 Dukes C patients and used immunohistochemistry to assess the relative expression level of SMAD4 and its value as a prognostic marker. In addition, SMAD4 was screened for mutations and two polymorphic microsatellite markers were used to assess the presence of allelic imbalance in these tumors. Patients with tumors expressing high SMAD4 levels had significantly better overall (P < 0.025) and disease-free (P < 0.013) survival than patients with low levels. This identifies SMAD4 as a prognostic marker for Dukes C colorectal cancer. Although all tumors with absent SMAD4 staining showed allelic imbalance in 18q21, tumors with 18q21 allelic imbalance as a group showed no difference in SMAD4 levels compared with tumors without allelic imbalance, suggesting that additional mechanisms of SMAD4 down-regulation exist. In addition, although SMAD4 mutations were found in five tumors, they were not associated with shorter survival. In conclusion, the level of expression of SMAD4 was found to be a more sensitive marker than 18q21 allelic imbalance and SMAD4 mutations, which were of no prognostic significance for these patients.

Key Words: SMAD4 • prognosis • colorectal cancer • Duke C • Immunohistochemistry

This article has been cited by other articles:

				G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5313 - 5327. [Abstract] [Full Text] [PDF]

				V. Davalos, H. Dopeso, J. Castano, A. J. Wilson, F. Vilardell, J. Romero-Gimenez, E. Espin, M. Armengol, G. Capella, J. M. Mariadason, et al. EPHB4 and Survival of Colorectal Cancer Patients. Cancer Res., September 15, 2006; 66(18): 8943 - 8948. [Abstract] [Full Text] [PDF]

				T. Watanabe, T. Kanazawa, Y. Kazama, J. Tanaka, T. Tanaka, S. Ishihara, and H. Nagawa SMAD4 Levels and Allelic Imbalance in 18q21 in Colorectal Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1654 - 1654. [Full Text] [PDF]

				D. Arango, P. Alhopuro, and L. A. Aaltonen Reply to the Letter to the Editor by Watanabe et al. Clin. Cancer Res., March 1, 2006; 12(5): 1654 - 1655. [Full Text] [PDF]

				H. Alazzouzi, V. Davalos, A. Kokko, E. Domingo, S. M. Woerner, A. J. Wilson, L. Konrad, P. Laiho, E. Espin, M. Armengol, et al. Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors Cancer Res., November 15, 2005; 65(22): 10170 - 10173. [Abstract] [Full Text] [PDF]

				P. Alhopuro, H. Alazzouzi, H. Sammalkorpi, V. Davalos, R. Salovaara, A. Hemminki, H. Jarvinen, J.-P. Mecklin, S. Schwartz Jr., L. A. Aaltonen, et al. SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6311 - 6316. [Abstract] [Full Text] [PDF]